Oncotype DX

Oncotype DX, is a multi-gene assay that quantifies the likelihood of disease recurrence in women with early-stage breast cancer and assesses the likely benefit from chemotherapy.Oncotype DX was developed and clinically validated by Genomic Health for women with early-stage breast cancer who are ER+ and whose lymph nodes are negative.

Oncotype DX analyzes a panel of 21 genes within a tumour to determine a Recurrence Score (RS). The Recurrence Score is a number between 0 and 100 that corresponds to a specific likelihood of breast cancer recurrence within 10 years of the initial diagnosis. With this information, it may be possible for doctors and patients to make more informed decisions about brest cancer treatment options.

Beginning 2009, Healthscope through Gribbles Pathology became a partner of Genomic Health, and can now assist both patients and doctors with Oncotype DX testing.

For further information on Oncotype DX click on the following links.

www.oncotypedx.com  or  www.mytreatmentdecision.com

Ordering Oncotype DX

For information on how to order Oncotype DX, please contact our product specialists on

0424 750 403  or  0402 563 020

or Email : oncotype@gribbles.com.au